Cargando…
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability
Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the...
Autores principales: | Lee, Donna M., Sun, Angela, Patil, Sneha S., Liu, Lijun, Rao, Aparna V., Trent, Parker T., Ali, Areej A., Liu, Catherine, Rausch, Jessica L., Presutti, Laura D., Kaczorowski, Adam, Schneider, Felix, Amankulor, Nduka M., Shuda, Masahiro, Duensing, Anette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117308/ https://www.ncbi.nlm.nih.gov/pubmed/35585158 http://dx.doi.org/10.1038/s41598-022-12000-2 |
Ejemplares similares
-
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells
por: Rausch, Jessica L., et al.
Publicado: (2020) -
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016) -
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors
por: Duensing, Stefan, et al.
Publicado: (2010) -
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
por: Heinrich, Michael C., et al.
Publicado: (2019) -
The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005)